Thadhani RI, Rosen S, Ofsthun NJ, et al. - Given intravenous vitamin D analogs afford the first-line treatment for the management of secondary hyperparathyroidism in hemodialysis patients in the US, and routine use of oral calcitriol (1,25-dihydroxyvitamin D₃) has been reported outside the US, and therefore, researchers undertook this retrospective cohort analysis wherein they analyzed patients on in-center hemodialysis receiving intravenous vitamin D who switched to oral calcitriol, to assess standard laboratory parameters of this patient group. Experts matched patients who switched to oral calcitriol (n = 2,280) to those receiving intravenous vitamin D (n = 2,280). Following the change to oral calcitriol, the oral calcitriol group, vs patients on intravenous vitamin D, exhibited lower mean calcium and phosphate levels. In contrast, higher intact parathyroid hormone levels were detected in the oral calcitriol group. Overall, findings revealed a largely similar aggregate of all mineral and bone laboratory parameters in range among patients receiving in-center hemodialysis who were switched to oral calcitriol vs those receiving an intravenous vitamin D analog.